Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

This study is testing a combination of low-dose whole-lung radiation, targeted high-dose radiation (SBRT), an immunotherapy drug (tislelizumab), and platinum-based chemotherapy given before surgery for stage IIA-IIIB non-small cell lung cancer that may be removable by surgery. **You may be eligible if...** - You are between 18 and 75 years old - You have untreated stage IIA-IIIB non-small cell lung cancer confirmed by biopsy or cell testing - Your tumor has been assessed by a surgical team as potentially removable - You have at least one measurable tumor on imaging - You can provide tumor tissue for PD-L1 testing **You may NOT be eligible if...** - You have already received treatment for this lung cancer - You have autoimmune disease or are on immune-suppressing medications - You have severe heart, lung, or other organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.